IL162680A0 - Non-nucleosidic inhibitors of reverse transcriptase as antagonists of cell proliferation and inducers of cell differenti - Google Patents

Non-nucleosidic inhibitors of reverse transcriptase as antagonists of cell proliferation and inducers of cell differenti

Info

Publication number
IL162680A0
IL162680A0 IL16268002A IL16268002A IL162680A0 IL 162680 A0 IL162680 A0 IL 162680A0 IL 16268002 A IL16268002 A IL 16268002A IL 16268002 A IL16268002 A IL 16268002A IL 162680 A0 IL162680 A0 IL 162680A0
Authority
IL
Israel
Prior art keywords
cell
differenti
inducers
antagonists
reverse transcriptase
Prior art date
Application number
IL16268002A
Other languages
English (en)
Original Assignee
Inst Superiore Di Sanita
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ITRM20010767 external-priority patent/ITRM20010767A1/it
Priority claimed from ITMI20021833 external-priority patent/ITMI20021833A1/it
Application filed by Inst Superiore Di Sanita filed Critical Inst Superiore Di Sanita
Publication of IL162680A0 publication Critical patent/IL162680A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL16268002A 2001-12-24 2002-12-23 Non-nucleosidic inhibitors of reverse transcriptase as antagonists of cell proliferation and inducers of cell differenti IL162680A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITRM20010767 ITRM20010767A1 (it) 2001-12-24 2001-12-24 Uso di 5.11-diidro-6h-dipirido1/4 3,2-b:2',3'-e|1/4 1.4|diazepine per la preparazione di composizioni farmaceutiche antitumorali.
ITMI20021833 ITMI20021833A1 (it) 2002-08-19 2002-08-19 Inibitori non nucleosidici della trascrittasi inversa come induttori del differenziamento cellulare.
PCT/EP2002/014727 WO2003055493A1 (en) 2001-12-24 2002-12-23 Non-nucleosidic inhibitors of reverse transcriptase as antagonists of cell proliferation and inducers of cell differentiation

Publications (1)

Publication Number Publication Date
IL162680A0 true IL162680A0 (en) 2005-11-20

Family

ID=26332794

Family Applications (2)

Application Number Title Priority Date Filing Date
IL16268002A IL162680A0 (en) 2001-12-24 2002-12-23 Non-nucleosidic inhibitors of reverse transcriptase as antagonists of cell proliferation and inducers of cell differenti
IL162680A IL162680A (en) 2001-12-24 2004-06-22 Use of non-nucleosidic inhibitors of reverse transcriptase for the preparation of pharmaceutical compositions for theraphy and / or prevention of pathologies characterized by loss of cellular differentiation and uncontrolled cell growth

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL162680A IL162680A (en) 2001-12-24 2004-06-22 Use of non-nucleosidic inhibitors of reverse transcriptase for the preparation of pharmaceutical compositions for theraphy and / or prevention of pathologies characterized by loss of cellular differentiation and uncontrolled cell growth

Country Status (22)

Country Link
US (1) US10507207B2 (de)
EP (1) EP1469858B1 (de)
JP (1) JP4336584B2 (de)
CN (1) CN100450487C (de)
AP (1) AP1958A (de)
AT (1) ATE400276T1 (de)
AU (1) AU2002358793B2 (de)
CA (1) CA2471543C (de)
CY (1) CY1108396T1 (de)
DE (1) DE60227563D1 (de)
DK (1) DK1469858T3 (de)
EA (1) EA007004B1 (de)
ES (1) ES2309222T3 (de)
HU (1) HU229522B1 (de)
IL (2) IL162680A0 (de)
MX (1) MXPA04006205A (de)
NZ (1) NZ534257A (de)
OA (1) OA13140A (de)
PL (1) PL211565B1 (de)
PT (1) PT1469858E (de)
SI (1) SI1469858T1 (de)
WO (1) WO2003055493A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2387405A2 (de) 2009-01-13 2011-11-23 ProteoSys AG Pirenzepin als mittel für die krebstherapie
CA2796620A1 (en) * 2010-06-04 2011-12-08 North-West University Injectable formulation
MX2015009546A (es) * 2013-01-23 2015-11-25 Alienor Farma Dosificacion aumentada de efavirenz para el tratamiento de cancer.
WO2016156557A1 (en) 2015-04-03 2016-10-06 Alienor Farma Monoclonal antibody to human line-1 orf2 protein and method for early detection of transforming cells in pre-neoplastic tissues of a human subject
CN113384585A (zh) * 2021-04-16 2021-09-14 蓝龙药业(北京)有限公司 依法韦仑在制备治疗小细胞肺癌的药物中的应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6258839B1 (en) * 1997-12-24 2001-07-10 Peter Mashava Isolation of naturally occuring isoflavanone and some clinical uses thereof

Also Published As

Publication number Publication date
JP2005513147A (ja) 2005-05-12
PL211565B1 (pl) 2012-05-31
US20060166970A1 (en) 2006-07-27
AP1958A (en) 2009-02-20
IL162680A (en) 2010-11-30
CN1607953A (zh) 2005-04-20
US10507207B2 (en) 2019-12-17
EP1469858B1 (de) 2008-07-09
WO2003055493A1 (en) 2003-07-10
DK1469858T3 (da) 2008-09-29
ES2309222T3 (es) 2008-12-16
AP2004003088A0 (en) 2004-09-30
MXPA04006205A (es) 2005-07-25
CN100450487C (zh) 2009-01-14
AU2002358793A1 (en) 2003-07-15
EP1469858A1 (de) 2004-10-27
DE60227563D1 (de) 2008-08-21
EA007004B1 (ru) 2006-06-30
CA2471543A1 (en) 2003-07-10
PL374038A1 (en) 2005-09-19
HUP0600841A3 (en) 2012-09-28
AU2002358793B2 (en) 2008-04-24
NZ534257A (en) 2008-03-28
HUP0600841A2 (en) 2007-05-02
CY1108396T1 (el) 2014-02-12
HU229522B1 (en) 2014-01-28
ATE400276T1 (de) 2008-07-15
SI1469858T1 (sl) 2008-10-31
EA200400861A1 (ru) 2004-12-30
CA2471543C (en) 2011-03-22
OA13140A (en) 2006-12-13
PT1469858E (pt) 2008-10-01
JP4336584B2 (ja) 2009-09-30
HK1074998A1 (zh) 2005-12-02

Similar Documents

Publication Publication Date Title
PL344248A1 (en) Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
PL369855A1 (en) 4-arylquinazolines and use thereof as nhe-3 inhibitors
EP1085871A4 (de) Quinazolinonehemmendern von cgmp phosphodiesterase
EP1383743A4 (de) Duale inhibitoren von pde 7 und pde 4
AU2002323337A1 (en) Use of dppiv inhibitors as diuretic and anti-hypertensive agents
SG80631A1 (en) Inhibitors of hiv reverse transcriptase
SI1373224T1 (sl) Novi spirotriciklični derivati in njihova uporaba kot zaviralci fosfodiesteraze-7
PL353535A1 (en) Application of selective pde 10 inhibitor and application of papaverine
PL374221A1 (en) Antibody inhibitors of gdf-8 and uses thereof
IL153246A0 (en) Substituted quinazoline derivatives and their use as inhibitors
HUP0304052A3 (en) Heterocyclic inhibitors of erk2 and uses thereof
IL161576A0 (en) Benzimidazoles and analogues and their use as protein kinases inhibitors
IL149100A0 (en) Heteroalkylamino-substituted bicyclic nitrogen heterocycles as inhibitors of p38 protein kinase
IL157109A0 (en) Quinazolines as mmp-13 inhibitors
ZA200501381B (en) New spirocondensed quinazolinones and their use as phosphodiesterase inhibitors
PL363011A1 (en) Bipiperidinyl-derivatives and their use as chemokine receptors inhibitors
EP1372654A4 (de) Chinolininhibitoren von hyak1- und hyak3-kinasen
IL159538A0 (en) 8/17 heterocyclic compounds and uses thereof as d-alanyl-d-alanine ligase inhibitors
AU1334602A (en) Osteopontin-coated surfaces and methods of use
AU2002356276A8 (en) Quinline derivates and their use as mek inhibitors
PL361733A1 (en) Sulfamidothienopyrimidines and the use of the same as phosphodiesterase v inhibitors
AP2004003088A0 (en) Non-nucleosidic inhibitors of reverse transcriptase as antagonists of cell proliferation and inducers of cell differentiation
PL363544A1 (en) Piperazino-derivatives and their use as pde4 inhibitor
IL156775A0 (en) Cyclic 2-carbonylaminoketones as inhibitors of cruzipain and other cysteine proteases
AU2002306845A1 (en) Telomerase inhibitors and methods of their use